Cannabidiol (CBD) and cannabigerol (CBG), non-psychoactive cannabis compounds, are showing significant promise in combating metabolic dysfunction associated steatotic liver disease (MASLD), the most common chronic liver condition worldwide.
A study by the HU School of Pharmacy found that both compounds trigger metabolic remodeling in the liver, boosting energy reserves and enhancing cellular cleanup processes. CBD and CBG increased phosphocreatine levels, supporting liver function under stress from high-fat diets.
They also restored activity of cathepsin enzymes responsible for clearing toxic fats and reduced harmful lipids like triglycerides and ceramides-linked to insulin resistance.
CBG demonstrated stronger effects on body fat reduction, insulin sensitivity, and lowering LDL cholesterol compared to CBD.
Researchers emphasize these findings open a path for plant-based therapies in treating metabolic liver disease, though human trials are needed.